Current Heart Failure Reports

, Volume 10, Issue 3, pp 185–189

Is There Still a Role for Ultrafiltration in the Management of Acute Heart Failure? CARRESS and Beyond

Decompensated Heart Failure (MM Givertz, Section Editor)

DOI: 10.1007/s11897-013-0142-z

Cite this article as:
Ryan, J. & Meng, S. Curr Heart Fail Rep (2013) 10: 185. doi:10.1007/s11897-013-0142-z

Abstract

The Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF) trial was a prospective, randomized study comparing ultrafiltration versus pharmacological therapy in the treatment of acute decompensated heart failure (ADHF) complicated by cardiorenal syndrome Bart et al. (N Eng J Med 367:2296–2304, 1). The study found that ultrafiltration was inferior to pharmacological therapy, resulting in a significant increase in serum creatinine and serious adverse events while producing no significant difference in weight loss. The CARRESS trial calls into question the viability of ultrafiltration as a preferable treatment strategy in ADHF patients with cardiorenal syndrome.

Keywords

Heart failureUltrafiltrationCardiorenal syndrome

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Pat and Jim Calhoun Cardiology CenterUCONN Health CenterFarmingtonUSA
  2. 2.Department of Internal MedicineUCONN Health CenterFarmingtonUSA